{"schemaVersion":1,"@context":"https://schema.org","@type":"Article","identifier":"2003_legacy_banyu_merck","headline":"万有製薬のTOB・MBO事例：MSD (Japan) / Merck & Co.（2003-01-09公表・2003年収録）","description":"万有製薬へのTOBは、Merckが残る49％を1,400円で取得し、上場子会社を完全所有へ移す取引だった。2003年にほぼ全株を取得したことは年次報告で確認できるが、完全取得の完了日は2004年3月30日であり、2003年のTOBだけで100％になったとは書けない。","canonicalUrl":"https://tobradar.com/tob/deals/2003-legacy_banyu_merck/","machineReadableUrl":"https://tobradar.com/tob-data/cases/2003-legacy_banyu_merck.json","catalogUrl":"https://tobradar.com/tob-data/cases.json","inLanguage":"ja","datePublished":"2026-07-19","dateModified":"2026-07-19","dataUpdatedAt":"2026-07-16T20:20:13.770Z","author":{"@type":"Person","name":"noru","url":"https://tobradar.com/about/"},"citation":[{"@type":"CreativeWork","identifier":"banyu-start","name":"Merck announces tender offer for full ownership of Banyu Pharmaceutical; Banyu board passes resolution of support for tender at meeting today","url":"https://www.sec.gov/Archives/edgar/data/64978/000095012303000210/y82447exv99.htm","datePublished":"2003-01-09","publisher":{"@type":"Organization","name":"Merck & Co. / SEC EDGAR"},"encodingFormat":"text/html"},{"@type":"CreativeWork","identifier":"banyu-later-primary","name":"Merck & Co., Inc. Annual Report 2004 (Exhibit 13)","url":"https://www.sec.gov/Archives/edgar/data/64978/000095012305003003/y06253exv13.htm","datePublished":"2005-03-11","publisher":{"@type":"Organization","name":"Merck & Co. / SEC EDGAR"},"encodingFormat":"text/html"},{"@type":"CreativeWork","identifier":"banyu-news-outcome","name":"Merck in deal to take full control of Japan drug firm","url":"https://www.telegraphindia.com/business/merck-in-deal-to-take-full-control-of-japan-drug-firm/cid/957620","datePublished":"2003-03-08","publisher":{"@type":"Organization","name":"The Telegraph India / AFP"},"encodingFormat":"text/html"}],"recommendedCitation":"TOBレーダー「万有製薬のTOB・MBO事例：MSD (Japan) / Merck & Co.（2003-01-09公表・2003年収録）」noru、記事確認 2026-07-19、https://tobradar.com/tob/deals/2003-legacy_banyu_merck/（参照日を追記）","citationGuidance":["確認済み事実はfactsのsourceIdsとsourcesを対応させて確認してください。","analysisはnoruの独自分析であり、リンク先原資料の記述とは区別してください。","limitationsに記載した未確認事項を断定しないでください。"],"record":{"dealId":"2003_legacy_banyu_merck","startDate":"2003-01-09","startStatus":"開始","startTitle":"MSD (Japan) / Merck & Co.、万有製薬に公開買付開始","startUrl":"https://www.sec.gov/Archives/edgar/data/64978/000095012303000210/y82447exv99.htm","caseUrl":"https://www.sec.gov/Archives/edgar/data/64978/000095012303000210/y82447exv99.htm","targetCode":"4515","targetName":"万有製薬","bidderName":"MSD (Japan) / Merck & Co.","relationLabel":"万有製薬←MSD (Japan) / Merck & Co.","offerPriceYen":1400,"offerPriceText":null,"announcementPriceYen":null,"announcementPriceText":null,"announcementPriceSource":null,"premiumPct":31.3,"premiumBasis":"2003-01-09終値までの1ヶ月平均終値","threeMonthPremiumPct":30.9,"tenderStartDate":"2003-01-14","tenderEndDate":"2003-03-06","tenderPeriodLabel":"2003-01-14 - 2003-03-06","tenderAgent":null,"subAgent":null,"tenderFilingYear":null,"listingStatus":null,"scheduleStatus":"closed","finalStatus":"成立","lastEventDate":"2003-03-07","lastEventTitle":"万有製薬TOBの結果、応募株式116,521,207株を取得しメルクグループ持株比率95.17%","lastEventUrl":"https://www.sec.gov/Archives/edgar/data/64978/000095012303000210/y82447exv99.htm","eventCount":2,"dealType":"TOB","isJapaneseTenderOfferFiling":true,"isMbo":false,"isSelfTender":false,"isHighPremium":true,"isLowPremium":false,"isDiscount":false,"generatedAt":"2026-06-08T07:19:33.669Z","sources":[{"title":"Merck announces tender offer for full ownership of Banyu Pharmaceutical","url":"https://www.sec.gov/Archives/edgar/data/64978/000095012303000210/y82447exv99.htm","source":"Merck / SEC","kind":"official","confidence":"high"},{"title":"万有製薬 株の95％米国メルクが取得へ","url":"https://www.mixonline.jp/tabid55.html?artid=27847","source":"ミクスOnline","kind":"news","confidence":"high"},{"title":"Nikkei Stock Index 300 - History of Component Change","url":"https://indexes.nikkei.co.jp/nkave/archives/file/history_of_nikkei_stock_index_300_component_changes_en.pdf","source":"日本経済新聞社","kind":"reference","confidence":"medium"}],"bidderCode":null,"year":2003,"caseStudyUrl":"https://tobradar.com/tob/deals/2003-legacy_banyu_merck/","caseStudyJsonUrl":"https://tobradar.com/tob-data/cases/2003-legacy_banyu_merck.json"},"research":{"schemaVersion":2,"year":2003,"dealId":"2003_legacy_banyu_merck","editorialStatus":"publish_ready","evidenceMode":"primary_verified","researchedAt":"2026-07-19","reviewedAt":"2026-07-19","author":"noru","reviewedBy":"noru","sources":[{"id":"banyu-start","tier":"primary","documentType":"tender_offer_announcement","publisher":"Merck & Co. / SEC EDGAR","title":"Merck announces tender offer for full ownership of Banyu Pharmaceutical; Banyu board passes resolution of support for tender at meeting today","url":"https://www.sec.gov/Archives/edgar/data/64978/000095012303000210/y82447exv99.htm","publishedAt":"2003-01-09","accessedAt":"2026-07-16","mediaType":"text/html"},{"id":"banyu-later-primary","tier":"primary","documentType":"annual_report","publisher":"Merck & Co. / SEC EDGAR","title":"Merck & Co., Inc. Annual Report 2004 (Exhibit 13)","url":"https://www.sec.gov/Archives/edgar/data/64978/000095012305003003/y06253exv13.htm","publishedAt":"2005-03-11","accessedAt":"2026-07-16","mediaType":"text/html"},{"id":"banyu-news-outcome","tier":"secondary","documentType":"news_report","publisher":"The Telegraph India / AFP","title":"Merck in deal to take full control of Japan drug firm","url":"https://www.telegraphindia.com/business/merck-in-deal-to-take-full-control-of-japan-drug-firm/cid/957620","publishedAt":"2003-03-08","accessedAt":"2026-07-19","mediaType":"text/html","accessMode":"browser_required","browserVerifiedAt":"2026-07-19"}],"facts":[{"id":"f-legacy-banyu-merck-1","text":"Merckは万有製薬の未保有49％、129,247,754株を対象に完全所有を目指す公開買付けを発表した。","sourceIds":["banyu-start"],"locator":"Merck発表・offer for remaining 49 percent","confidence":"confirmed"},{"id":"f-legacy-banyu-merck-2","text":"買付期間は2003年1月14日から3月6日までの52日間で、買付価格は1株1,400円だった。","sourceIds":["banyu-start"],"locator":"Merck発表・tender period and price","confidence":"confirmed"},{"id":"f-legacy-banyu-merck-3","text":"1,400円は1か月平均株価を31.3％、3か月平均株価を30.9％上回ると説明された。","sourceIds":["banyu-start"],"locator":"Merck発表・premiums to average prices","confidence":"confirmed"},{"id":"f-legacy-banyu-merck-4","text":"万有製薬取締役会は2003年1月9日に公開買付けへの賛同を決議した。","sourceIds":["banyu-start"],"locator":"Merck発表・Banyu board support","confidence":"confirmed"},{"id":"f-legacy-banyu-merck-5","text":"Merckの2004年年次報告は、2003年に公開買付けを通じて万有製薬株式のほぼ全てを取得したと記録する。","sourceIds":["banyu-later-primary"],"locator":"Merck 2004 Annual Report・Banyu acquisition","confidence":"confirmed"},{"id":"f-legacy-banyu-merck-6","text":"同年次報告は万有製薬の完全取得が2004年3月30日に完了したと記録する。","sourceIds":["banyu-later-primary"],"locator":"Merck 2004 Annual Report・completion date","confidence":"confirmed"},{"id":"f-legacy-banyu-merck-7","text":"2003年3月8日の同時期報道は、買付け後のMerck側持分を約95％と伝え、価格に異論を述べた投資家がいたことも報じた。","sourceIds":["banyu-news-outcome"],"locator":"AFP配信記事・post-offer stake and objections","confidence":"qualified"}],"analysis":{"lead":{"text":"万有製薬へのTOBは、Merckが残る49％を1,400円で取得し、上場子会社を完全所有へ移す取引だった。2003年にほぼ全株を取得したことは年次報告で確認できるが、完全取得の完了日は2004年3月30日であり、2003年のTOBだけで100％になったとは書けない。","evidence":["f-legacy-banyu-merck-1","f-legacy-banyu-merck-2","f-legacy-banyu-merck-5","f-legacy-banyu-merck-6"]},"background":[{"text":"Merckは既に万有製薬の過半を保有しており、本件は新規参入ではなく残存少数株主の持分を取り込む支配完成型の買付けだった。対象取締役会が賛同したため取引実行の対立は小さかったとみられるが、親会社と少数株主の価格利害はなお分離して評価する必要がある。","evidence":["f-legacy-banyu-merck-1","f-legacy-banyu-merck-4","f-legacy-banyu-merck-7"]},{"text":"129,247,754株は開始時の対象株数であり、取得実績ではない。年次報告の「ほぼ全て」と同時期報道の「約95％」は結果の大勢を示すものの、現行リストの116,521,207株・95.17％を正式結果原本なしに確定値として本文へ移さない。","evidence":["f-legacy-banyu-merck-1","f-legacy-banyu-merck-5","f-legacy-banyu-merck-7"]}],"rationale":[{"text":"完全所有に近づけば、Merckは研究開発、製品導入、販売資源の配分を少数株主との上場会社手続から切り離して進めやすい。年次報告も日本での地位強化を取引の意味としており、主眼は短期的な株式売買益ではなく医薬品事業の統合だった。","evidence":["f-legacy-banyu-merck-1","f-legacy-banyu-merck-5","f-legacy-banyu-merck-6"]},{"text":"一方、上場子会社の完全取得では親会社が買付価格を提示するため、公正な価格形成が中心課題になる。取締役会賛同は手続上重要だが、同時期報道に投資家の価格異論がある以上、賛同決議だけで少数株主への価値配分が十分だったとは判断しない。","evidence":["f-legacy-banyu-merck-3","f-legacy-banyu-merck-4","f-legacy-banyu-merck-7"]}],"premiumView":{"text":"1,400円は短期と3か月の平均株価を約31％上回った。複数期間に対して似た上乗せ率であるため、一時的な終値だけに依存した説明ではないが、事業計画やDCFのレンジは今回の資料から再現できず、完全支配が生む固有価値まで価格に含まれたかは未確定である。","evidence":["f-legacy-banyu-merck-2","f-legacy-banyu-merck-3"]},"shareholderAngle":{"text":"応募株主は約31％の平均株価プレミアムで退出でき、残る株主は約95％の支配株主の下で将来の完全取得を待つ立場になった。2004年3月の完全取得まで段階が残ったため、その間の情報開示、残余持分の処理条件、上場維持判断が少数株主にとって重要だった。","evidence":["f-legacy-banyu-merck-3","f-legacy-banyu-merck-5","f-legacy-banyu-merck-6","f-legacy-banyu-merck-7"]},"outcomeAssessment":{"text":"Merckの一次年次報告により、2003年にほぼ全株を取得し、翌年3月30日に完全取得した流れは閉じる。もっとも、2003年の正式結果通知がなく、正確な応募株数とTOB直後比率は二次報道以上に確認できないため、取引の方向と最終完了は確認済み、当初TOBの数量実績は留保付きと評価する。","evidence":["f-legacy-banyu-merck-5","f-legacy-banyu-merck-6","f-legacy-banyu-merck-7"]},"limitations":[{"text":"開始条件はSEC掲載の当事者発表、最終的な完全取得はMerck年次報告で確認できる。しかし2003年TOBの正式結果原本がなく、約95％は同時期報道の値である。予定対象株数と応募実績を分け、2003年時点の正確な応募・取得株数は断定しない。","evidence":["f-legacy-banyu-merck-1","f-legacy-banyu-merck-5","f-legacy-banyu-merck-6","f-legacy-banyu-merck-7"]}]}}}